| Bioactivity | SD-169 is an orally active ATP-competitive inhibitor of p38α MAPK, with an IC50 of 3.2 nM. SD-169 also weakly inhibits p38β MAPK with an IC50 of 122 nM. SD-169 prevents the development and progression of diabetes by inhibiting T cell infiltration and activation[1]. |
| Invitro | SD-169 significantly reduces p38 and HSP60 expression in T cells of the pancreatic beta islets[1].SD-169 demonstrates 38-fold potency against p38α MAP kinase (IC50=3.2 nM) than p38β MAP kinase (IC50=122 nM)[1]. |
| Name | SD-169 |
| CAS | 1670-87-7 |
| Formula | C9H8N2O |
| Molar Mass | 160.18 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |
| Reference | [1]. Medicherla S, et al. Preventive and therapeutic potential of p38 alpha-selective mitogen-activated protein kinase inhibitor in nonobese diabetic mice with type 1 diabetes. J Pharmacol Exp Ther. 2006 Jul;318(1):99-107. |